OPKO reported Q4 2025 total revenue of 148500000 and a net loss of -31300000, driven by a consolidated operating loss of -38300000. Services revenue declined due to BioReference asset sales and lower volumes, while product revenue increased and IP/other revenue included a Regeneron upfront payment and Eli Lilly royalty revenue.

OPKO Health reported a total revenue of $149.9 million and a net loss of $67.6 million for the first quarter of 2025. The company signed a definitive agreement with Labcorp to sell oncology and related clinical testing assets for up to $225 million and entered into a collaboration agreement with Entera Bio to advance an oral GLP-1/glucagon tablet candidate.

OPKO Health, Inc. announced its fourth quarter 2024 results, reporting total revenues of $183.6 million, a slight increase from the previous year. The company achieved a net income of $14.0 million, a substantial improvement from a net loss of $66.5 million in the prior year, primarily due to a $54.1 million gain from the sale of GeneDx shares and $21.4 million in non-cash other income.

OPKO Health reported a profitable third quarter, driven by a $121.5 million gain from the sale of BioReference assets and a $10.5 million gain from the sale of GeneDx shares. Revenue was $173.6 million, and net income was $24.9 million, or $0.03 per diluted share, compared to a net loss in the prior year.

OPKO Health reported a decrease in consolidated total revenues to $182.2 million compared to $265.4 million for the same period in 2023. The operating loss was $61.7 million, a significant change from the $7.0 million operating income in the prior year. Net loss was $10.3 million, or $0.01 per share, compared to a net loss of $19.6 million, or $0.03 per share, in the previous year.

OPKO Health reported a decrease in total revenues to $173.7 million in Q1 2024 from $237.6 million in Q1 2023. The operating loss increased to $71.5 million from $30.6 million, and the net loss was $81.8 million, or $0.12 per share, compared to a net loss of $18.3 million, or $0.02 per share, in the prior year period. The company's cash and cash equivalents were $75.6 million as of March 31, 2024.

OPKO Health reported a decrease in consolidated total revenues to $181.9 million, compared to $185.4 million for the same period in 2022. The operating loss increased to $69.1 million, compared to $55.3 million in the prior year. Net loss was $65.5 million, or $0.09 per share, compared to a net loss of $85.2 million, or $0.11 per share, for the 2022 quarter.

OPKO Health reported consolidated total revenues of $178.6 million, compared to $179.7 million for the comparable 2022 period. The operating loss was $64.4 million for the third quarter of 2023, compared to an operating loss of $87.8 million for the 2022 quarter. Net loss for the third quarter of 2023 was $84.5 million, or $0.11 per share, compared with a net loss of $86.1 million, or $0.11 per share, for the 2022 quarter.

OPKO Health reported a decrease in consolidated total revenues to $265.4 million compared to $309.9 million in the same period last year. The company experienced an operating income of $7.0 million, a significant improvement from the operating loss of $10.7 million in the previous year. Net loss was $19.6 million, or $0.03 per share, compared to a net loss of $101.7 million, or $0.14 per share, for the 2022 quarter.

OPKO Health reported a decrease in consolidated total revenues to $237.6 million compared to $329.2 million for the same period in 2022. The operating loss decreased to $30.6 million from $72.4 million in the previous year, and the net loss was $18.3 million, or $0.02 per share, compared to a net loss of $55.4 million, or $0.08 per share, for the 2022 quarter.

OPKO Health's Q4 2022 revenue decreased compared to the previous year, primarily due to lower COVID-19 testing volume in the diagnostics segment. The company reported a net loss, including a non-cash expense related to the fair value of its GeneDx Holdings investment.

OPKO Health's Q3 2022 revenue was $179.7 million, a decrease from $385.8 million in the same period of 2021. The company experienced an operating loss of $87.8 million, compared to an operating income of $37.8 million in Q3 2021. Net loss for the quarter was $86.1 million, or $0.11 per share, a significant shift from the net income of $28.7 million, or $0.04 per diluted share, in the prior year.

OPKO Health reported a decrease in consolidated total revenues, driven by lower COVID-19 testing volume and a decrease in revenue from services. The company experienced an operating loss, and net loss was significantly impacted by a non-cash expense related to a decrease in Sema4's stock price.

OPKO Health reported consolidated total revenues of $329.2 million for the first quarter of 2022, compared to $545.2 million for the comparable period in 2021. The operating loss for the first quarter of 2022 was $72.4 million, compared to an operating income of $38.5 million for the 2021 quarter. Net loss for the first quarter of 2022 was $55.4 million, or $0.08 per share, compared to net income of $31.1 million, or $0.05 per diluted share, for the 2021 quarter.

OPKO Health reported a decrease in consolidated total revenues to $401.3 million compared to $494.6 million for the same period in 2020. The company experienced an operating loss of $63.1 million, a net loss of $73.8 million, and a diluted loss per share of $0.11. The decline was primarily due to decreased COVID-19 testing volume and increased investments in BioReference Laboratories' base business and digital health activities.

OPKO Health reported a decrease in consolidated total revenues to $385.8 million compared to $428.1 million for the same period in 2020. However, operating income increased by 72% to $37.8 million, and net income was $28.7 million, or $0.04 per diluted share.

OPKO Health reported consolidated total revenues of $442.4 million for Q2 2021, compared to $301.2 million for the comparable period in 2020. However, the company experienced a net loss of $16.2 million, or $0.03 per share, compared to net income of $33.7 million, or $0.05 per diluted share, for the same period in 2020. The decrease in profitability was primarily due to increased costs and expenses.

OPKO Health reported consolidated revenues of $545.2 million and a net income of $31.1 million, or $0.05 per diluted share, for the first quarter of 2021. This is compared to $211.5 million in revenues and a net loss of $59.1 million, or $0.09 per share, for the comparable period of 2020.

OPKO Health reported a net income of $32.3 million for the fourth quarter of 2020, a significant turnaround from the net loss of $112.4 million in the same period of 2019. Consolidated revenues increased to $494.6 million, driven by a surge in diagnostics revenue from COVID-19 testing.

OPKO Health reported a net income of $23.7 million for the third quarter of 2020, a significant turnaround from the net loss of $62.0 million in the same period of 2019. Consolidated revenues increased to $428.1 million, compared to $228.8 million in the prior year, primarily driven by increased COVID-19 testing volumes and pharmaceutical product sales.

OPKO Health reported a strong second quarter, driven by increased COVID-19 testing volumes at BioReference Laboratories. The company achieved consolidated revenues of $301.2 million, a significant increase compared to $226.4 million in the same period last year. Net income for the quarter was $33.7 million, a substantial improvement from the net loss of $59.8 million in the prior year.

OPKO Health reported a decrease in consolidated revenues to $211.5 million compared to $222.5 million for the comparable period of 2019. The net loss for the quarter was $59.1 million, an improvement from the $80.8 million net loss in the first quarter of 2019. BioReference Laboratories launched COVID-19 testing nationwide and RAYALDEE prescriptions increased by 78%.

OPKO Health reported an increase in consolidated revenues for Q4 2019 to $224.3 million compared to $221.9 million in Q4 2018. The net loss for the quarter was $112.4 million, or $0.18 per share, compared to a net loss of $76.1 million, or $0.13 per share, for the comparable period of 2018. The company's cash, cash equivalents, and marketable securities totaled $85.5 million as of December 31, 2019.